Nuvation Bio’s manufacturing milestone with Thermo Fisher

Nuvation Bio (NUVB) has completed the process technology transfer and product introduction for its lead therapy IBTROZI (taletrectinib) to Thermo Fisher Scientific in the US, a step that directly affects future drug supply.

This transition, submitted as a supplement to Nuvation Bio’s IBTROZI New Drug Application for advanced or metastatic ROS1-positive non small cell lung cancer, positions Thermo Fisher as the company’s US manufacturer for the drug product.

Despite the completed tech transfer and US manufacturing set up for IBTROZI, Nuvation Bio’s share price has slipped over recent months, with a 30 day share price return of 4.09% lower and a 90 day share price return of 15.65% lower, although the 1 year total shareholder return is 109.38% and the 3 year total shareholder return is very large at almost 3x. This points to momentum that has cooled but not reversed.

If this oncology story has your attention, it can be worth seeing what else is moving in related areas by checking out 34 healthcare AI stocks

With Nuvation Bio’s shares down over the past 3 and 12 months but still showing a very large total return over 3 years, and trading at a steep discount to analyst targets, is the stock mispriced, or is future growth already priced in?

Most Popular Narrative: 54.2% Undervalued

At a last close of $4.69 versus a narrative fair value of $10.25, the current price sits well below what this widely followed view considers reasonable, setting up a valuation story built around future growth and margin change.

Advancement of safusidenib into a pivotal Phase III high grade IDH1 mutant glioma maintenance study, targeting a population underserved by existing therapies, could position the company to tap into a durable brain tumor market and add a second meaningful revenue pillar that has the potential to scale earnings beyond IBTROZI.

Want to understand why this fair value sits so far above the current share price? The narrative leans on steep revenue growth, margin improvement and a future earnings profile that contrasts sharply with today. The exact mix of product ramp, geographic expansion and long dated earnings assumptions is where the story gets interesting.

Result: Fair Value of $10.25 (UNDERVALUED)

However, you still need to watch for delays in the long dated safusidenib trial and tougher competition in ROS1 targeted therapies that could weaken this growth narrative.

Another Angle on Valuation

The narrative fair value of $10.25 already frames Nuvation Bio as undervalued, but the current P/S ratio of 11.4x tells a tougher story. It sits well above peers at 6x and the wider US Pharmaceuticals group at 5.4x, even though the fair ratio points to 12.4x as a level the market could move toward. For you, that mix of apparent upside and rich revenue pricing raises a simple question: is the discount a genuine opportunity or compensation for execution and profitability risk?

To stress test that question against the revenue based view, it is worth looking at a fuller breakdown of how this P/S compares to peers, the industry and the fair ratio in one place, and seeing what the numbers say about valuation risk and potential upside in practice, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If the mix of optimism and concern around Nuvation Bio feels finely balanced, consider reviewing the core data for yourself, then weigh up the 2 key rewards and 1 important warning sign

Looking for more investment ideas?

If Nuvation Bio is on your radar, do not stop here. Broaden your watchlist with other clear setups that could sharpen your portfolio thinking and opportunities.

• Spot potential value opportunities early by scanning screener containing 22 high quality undiscovered gems that many investors may not be watching yet.
• Strengthen your defensive side by focusing on companies in the 65 resilient stocks with low risk scores that score well on resilience.
• Target quality at a discount by reviewing the 46 high quality undervalued stocks that combine appealing prices with solid fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.